The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

The Globe and Mail has
updated our Stock Quote Pages
You are about to experience the newly designed Stock Quote Pages format. With the new layout, you'll enjoy a more in-depth look at the companies you're following and pages that are easier to navigate. This Editors' blog post explains why we've made these changes.

 

Jazz Pharmaceuticals PLC

Nasdaq: JAZZ
Last

(U.S.) $164.96

Today's change-4.07 -2.41%
Updated December 22 4:00 PM EST. Delayed by at least 15 minutes.
 

Jazz Pharmaceuticals PLC

Nasdaq: JAZZ
Last

(U.S.) $164.96

Today's change-4.07 -2.41%
Updated December 22 4:00 PM EST. Delayed by at least 15 minutes.

Jazz Pharmaceuticals PLC crosses below 50-day moving average

Jazz Pharmaceuticals PLC closed sharply lower Monday, dropping (U.S.)$4.07 or 2.41% to (U.S.)$164.96 and crossing below its 50-day moving average. Over the last five days, shares have gained 1.45% and 30.34% year to date. Shares have outperformed the S&P 500 by 18.82% during the last year.

Key company metrics

  • Open(U.S.) $169.05
  • Previous close(U.S.) $169.03
  • High(U.S.) $169.95
  • Low(U.S.) $164.25
  • Bid / Ask(U.S.) $164.90 / (U.S.) $171.95
  • YTD % change+30.34%
  • Volume475,035
  • Average volume (10-day)908,382
  • Average volume (1-month)945,624
  • Average volume (3-month)775,618
  • 52-week range(U.S.) $120.38 to (U.S.) $183.84
  • Beta0.66
  • Trailing P/E388.72×
  • P/E 1 year forward20.37×
  • Forward PEG0.82×
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) $0.42
Updated December 22 4:00 PM EST. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+2.87%

Based on its net profit margin of 2.87%, Jazz Pharmaceuticals PLC is less effective than other companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX0.25%Sector:Industry:
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q3/2014Q2/2014Q1/2014Q4/2013
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedSep 30, 201409/30/2014Jun 30, 201406/30/2014Mar 31, 201403/31/2014Dec 31, 201312/31/2013
Revenue307291247236
Total other revenue--------
Total revenue307291247236
Gross profit280261216210
Total cost of revenue27313126
Total operating expense249217314141
Selling / general / administrative9410110681
Research & development972014514
Depreciation / amortization31333121
Interest expense (income), net operating--------
Unusual expense (income)033--0
Other operating expenses, total--------
Operating income5874-6794
Interest income (expense), net non-operating-15-11-10-6
Gain (loss) on sale of assets--------
Other--------
Income before tax5063-7787
Income after tax2644-9455
Income tax, total24191732
Net income2644-9355
Total adjustments to net income--------
Net income before extra. items2644-9355
Minority interest001--
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items2644-9355
Inc. avail. to common incl. extra. items2644-9355
Diluted net income2644-9355
Dilution adjustment----0--
Diluted weighted average shares63625962
Diluted EPS excluding extraordinary itemsvalue per share0.410.70-1.580.90
Dividends per sharevalue per share0.000.000.00--
Diluted normalized EPSvalue per share0.261.13-1.380.95